Similar articles

• Role of the interleukin 24 in patients with ulcerative colitis.

  Camarillo GF, Furuzawa-Carballeda J, Martínez-Benítez B, Barreto-Zúñiga R, Yamamoto-Furusho JK. Camarillo GF, et al. Inflamm Bowel Dis. 2011 Oct;17(10):2209-10. doi: 10.1002/ibd.21635. Epub 2011 Feb 1. Inflamm Bowel Dis. 2011. PMID: 21287675 No abstract available.
• Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis.

  Yamamoto-Furusho JK, Peñaloza-Coronel A, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-Lopez A. Yamamoto-Furusho JK, et al. Inflamm Bowel Dis. 2011 Feb;17(2):680-1. doi: 10.1002/ibd.21322. Inflamm Bowel Dis. 2011. PMID: 20848495 No abstract available.
• High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.

  Xu AT, Li Y, Zhao D, Shen J, Xu XT, Qiao YQ, Zhu MM, Wang TR, Cui Y, Ai LY, Ran ZH. Xu AT, et al. Inflamm Bowel Dis. 2015 Feb;21(2):241-50. doi: 10.1097/MIB.0000000000000267. Inflamm Bowel Dis. 2015. PMID: 25545374
• Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis.

  Gan HT, Chen YQ, Ouyang Q. Gan HT, et al. J Gastroenterol Hepatol. 2005 Jul;20(7):1016-24. doi: 10.1111/j.1440-1746.2005.03862.x. J Gastroenterol Hepatol. 2005. PMID: 15955209
• Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease.

  Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R, Hermoso MA. Beltrán CJ, et al. Inflamm Bowel Dis. 2010 Jul;16(7):1097-107. doi: 10.1002/ibd.21175. Inflamm Bowel Dis. 2010. PMID: 20014018